close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.20 +0.34 (+1.28%)
Streaming Delayed Price Updated: 9:42 AM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
40 41 Next >
News headline image
Pfizer Reports Fourth-Quarter and Full-Year 2021 Results
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Announces New Chief Development Officer
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and AWS Working Together to Speed Up Clinical Operations Trials
New York, NY -- (SBWIRE) -- 01/28/2022 -- Technology is vital to optimizing the process of clinical operations trials in the near future - and this has been brought one step closer by the news that... 
Via SBWire
News headline image
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
From Pfizer Inc.
Via Business Wire
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,... 
Via FinancialNewsMedia
Topics Death Intellectual Property
News headline image
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
From Pfizer Inc.
Via Business Wire
Dietary Supplements Market Growing at a CAGR of 7.0% | Key Players are Amway, Herbalife Nutrition, ADM, Pfizer, Abbott Laboratories, Bayer, Glanbia, Nature’s Sunshine Products
Via AB Newswire
News headline image
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
From Pfizer Inc.
Via Business Wire
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s... 
Via FinancialNewsMedia
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
New York, NY, and Tel Aviv, ISRAEL - (NewMediaWire) - January 18, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today released videos of... 
Via NewMediaWire
News headline image
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
From Pfizer Inc.
Via Business Wire
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer... 
Via FinancialNewsMedia
Topics Death
DGE’s Investigator Initiated Trials Summit
Via Investor Brand Network
News headline image
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
From Pfizer Inc.
Via Business Wire
With Full Enrollment Complete In Its Phase 2 COVID-Related GI Treatment Trial, First Wave Bio Could Earn An EUA Sooner Than Later (NASDAQ: FWBI)
Via AB Newswire
News headline image
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
From Pfizer Inc.
Via Business Wire
New Study Explores Whether mRNA Vaccines Could Help Against Cancer
Via Investor Brand Network
News headline image
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
News headline image
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir(TM) Phase 2 & COVID Testing
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
From Pfizer Inc.
Via Business Wire
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today